ADMA Biologics, Inc. (ADMA)

$2.62

-0.08 (-2.96%)
Rating:
Recommendation:
Buy
Symbol ADMA
Price $2.62
Beta 0.919
Volume Avg. 2.69M
Market Cap 500.051M
Shares () -
52 Week Range 1.01-2.92
1y Target Est -
DCF Unlevered ADMA DCF ->
DCF Levered ADMA LDCF ->
ROE -60.28% Strong Sell
ROA -24.63% Sell
Operating Margin -
Debt / Equity 159.56% Buy
P/E -
P/B 4.50 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest ADMA news


Mr. Adam Grossman
Healthcare
Biotechnology
NASDAQ Global Market

ADMA Biologics, Inc., a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. It offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. The company also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, it operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.